Low-Dose Caffeine May Improve Aerobic Time-Trial Performance
A meta-analysis of placebo-controlled crossover trials found reduced aerobic time-trial completion times with both low- and moderate-dose oral anhydrous caffeine, but the evidence was mostly derived from male participants, cycling studies, and trials using doses no higher than 6 mg/kg.
Clinical Report: Low-Dose Caffeine May Improve Aerobic Time-Trial Performance
Overview
A systematic review and meta-analysis found that low-dose caffeine supplementation is associated with improvements in aerobic time-trial performance in healthy adults. The analysis included 48 trials and demonstrated significant reductions in completion times for both low and moderate doses of caffeine.
Background
Caffeine is widely used as an ergogenic aid in sports and exercise, with potential benefits for performance enhancement. Understanding the effects of different caffeine doses on aerobic performance is crucial for athletes and healthcare professionals.
Data Highlights
Caffeine Dose
Standardized Mean Difference (SMD)
Completion Time Reduction
Low Dose (1.3-3 mg/kg)
-0.27 (95% CI, -0.44 to -0.11; p = .001)
~2.14%
Moderate Dose (4-6 mg/kg)
-0.52 (95% CI, -0.77 to -0.28; p < .0001)
~2.18%
Key Findings
Low-dose caffeine (1.3-3 mg/kg) significantly reduced aerobic time-trial completion time compared to placebo.
Moderate-dose caffeine (4-6 mg/kg) also showed significant reductions in completion time.
Mean completion-time reductions for low and moderate doses were approximately 2.14% and 2.18%, respectively.
Interindividual variability in caffeine responsiveness was noted, particularly related to CYP1A2 genotypes.
Only 11 of the 48 trials had a low risk of bias, indicating potential limitations in the evidence quality.
Clinical Implications
Healthcare professionals should consider individual responses to caffeine supplementation for improving aerobic performance in healthy adults, noting variability based on genetic factors.
Conclusion
The findings indicate that low-dose caffeine is associated with enhanced aerobic time-trial performance.
